Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: relevance of Kohne's risk classification.

Date publication

avril 2013

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Desot E, de Mestier L, Volet J, Delmas C, Garcia B, Geoffroy P, Abdelli N, Baule M, Dubroeucq O, Marquis E, Bouche O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/23201298

Résumé

BACKGROUND: Kohne's prognostic classification has been previously proposed, based on performance status, alkaline phosphatase level, number of metastatic sites and white blood cells count. AIMS: To identify prognostic factors for survival and to assess the validity of Kohne's classification, in the era of targeted biotherapies, in patients treated with chemotherapy for non resectable metastatic colorectal cancer. METHODS: A total of 290 consecutive patients were retrospectively identified in all gastroenterology units of one French county, between 2004 and 2008. Univariate and multivariate analysis for overall survival were performed using pre-treatment patient characteristics. RESULTS: All data were available for prognostic categorization in 133 patients. Median survival was 22.1 months. The distribution and median survival for Kohne's prognostic groups were as following: good (n=73; 24.8 months), intermediate (n=35; 24.2 months), and poor (n=25; 7.0 months). The survival difference was significant between good and poor prognostic groups (p

Référence

Dig Liver Dis. 2013 Apr;45(4):330-5